BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors

NOVATO, Calif., Sept. 23 /PRNewswire-FirstCall/ — BioMarin
Pharmaceutical Inc. (Nasdaq:
BMRN) announced today the appointment of William D. Young and
Kenneth M. Bate to its Board of Directors.

“We are extremely pleased to welcome William Young and Kenneth
Bate to our Board of Directors.  With experience, vision and
proven strength in leadership and execution, they are both
exceptionally qualified to take on this important role in the
company,” said Pierre Lapalme, Chairman of the Board of Directors
of BioMarin. “With four products on the market and six product
candidates in the clinic by early next year, BioMarin is the
busiest it has ever been, and I am confident that Mr. Young and Mr.
Bate will serve as valuable leaders and contributors to the growth
of the company during this exciting time.”

Mr. William D. Young is a Venture Partner at Clarus Ventures of
San Francisco and Boston. He was appointed Chairman of the Board of
Biogen Idec in January 2010 and began serving as a Director of IDEC
Pharmaceuticals in 1997. From 1999 to October 2009, Mr. Young was
Chairman and Chief Executive Officer for Monogram Biosciences,
Inc., a pioneer in the field of personalized medicine. From 1997 to
1999, Mr. Young served as Chief Operating Officer of Genentech,
Inc. Mr. Young joined Genentech in 1980 as Director of
Manufacturing and Process Sciences and became Vice President in
1983. He was promoted to various positions and, in 1997, became
Chief Operating Officer, taking on responsibility for all
development, operations and sales and marketing activities. Prior
to joining Genentech, Mr. Young was with Eli Lilly & Co. for 14
years. Mr. Young holds a B.S. in Chemical Engineering from Purdue
University and a M.B.A. from Indiana University and an Honorary
Doctorate in Engineering from Purdue University. He is also a
Director of Theravance, Inc. Mr. Young was elected to the Na

‘/>”/>

SOURCE